Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

e update today, Wednesday, May 7, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Jack Lief, President and Chief Executive Officer and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer will host the conference call.

The conference call may be accessed by dialing 866.356.3095 for domestic callers and 617.597.5391 for international callers. Please specify to the operator that you would like to join the "Arena First Quarter Earnings Call." The participant code for the call is 65484912. The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Upcoming Corporate Presentations

Arena is scheduled to present at several investment and industry conferences through June 2008, including:

o Bank of America 2008 Health Care Conference, May 13-15, 2008,

Las Vegas, Nevada

o Citigroup's Global Healthcare Conference, May 21-22, 2008,

New York, New York

o The Seventh Annual Needham & Company, LLC Biotechnology and Medical

Technology Conference, June 11-12, 2008, New York, New York

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independ
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):UT Southwestern receives $700,000 from HHMI to promote medical education of Ph.D. students 2The pitch of blue whale songs is declining around the world, scientists discover 2The pitch of blue whale songs is declining around the world, scientists discover 3McGill University receives almost 2463 million under CFI program to support five research projects 8910 1McGill University receives almost 2463 million under CFI program to support five research projects 8910 2McGill University receives almost 2463 million under CFI program to support five research projects 8910 3Is Your Teenager Using Prescription Drugs Behind Your Back 3F 0ATestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription 49431 1Is Your Teenager Using Prescription Drugs Behind Your Back 3F 0ATestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription 49431 2Is Your Teenager Using Prescription Drugs Behind Your Back 3F 0ATestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription 49431 3National All Schedules Prescription Electronic Reporting 28NASPER 29 Act Receives Senate Support 49429 1National All Schedules Prescription Electronic Reporting 28NASPER 29 Act Receives Senate Support 49429 2National All Schedules Prescription Electronic Reporting 28NASPER 29 Act Receives Senate Support 49429 3